newsfilter
← Latest News
Business Wire·

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia's novel small-molecule inhibitors Enodia Therapeutics, a biotechnology company